During Friday’s Current trade, Shares of Legg Mason Inc (NYSE:LM), lost -1.06% to $42.07.
Legg Mason, Inc. (LM) stated preliminary assets under administration of $681.9 billion as of August 31, 2015. This month’s AUM reflects long-term outflows of $1.2 billion, counting equity outflows of $1.7 billion partially offset by fixed income inflows of $0.5 billion. Liquidity inflows were $3.4 billion and this month’s AUM reflects $0.5 billion in negative foreign exchange impact.
Legg Mason, Inc. is a publicly owned asset administration holding company. The firm provides investment administration and related services to institutional and individual clients, company-sponsored mutual funds and other pooled investment vehicles through its wholly owned auxiliaries. Legg Mason, Inc. was founded in 1899 and is based in Baltimore, Maryland.
Shares of Commscope Holding Company Inc (NASDAQ:COMM), declined -2.04% to $32.24, during its current trading session.
CommScope Holding Company, Inc., a global leader in infrastructure solutions for communications netoperates, plans to take part in the following conferences:
- Credit Suisse Small & Mid Cap Conference
Date: Wednesday, September 16, 2015
Time: 8:50 a.m. EDT - Deutsche Bank 2015 Technology Conference
Date: Thursday, September 17, 2015
Time: 2:00 p.m. EDT
CommScope Holding Company, Inc., together with its auxiliaries, provides connectivity and infrastructure solutions for wireless, business enterprise, and residential broadband netoperates worldwide. The company operates through three segments: Wireless, Enterprise, and Broadband. The Wireless segment offers macro cell site solutions primarily under the Andrew brand, counting base station antennas, microwave antennas, hybrid fiber-feeder and power cables, coaxial cables, connectors, amplifiers, filters, and backup power solutions; and small cell distributed antenna systems (DAS) solutions that allow wireless operators to enhance spectral efficiency, and cellular coverage and capacity in network conditions, such as commercial buildings, urban areas, stadiums, and transportation systems. T
Tahoe Resources Inc (NYSE:TAHO), during its Thursday’s current trading session decreased -2.72% to $7.50.
Tahoe Resources Inc. (TAHO) is happy to declare its ninth monthly dividend for 2015 of USD$0.02 per common share. Shareholders of record at the close of business on Thursday, September 17, 2015 will be entitled to receive payment of this dividend on Thursday, September 24, 2015 .
Tahoe Resources Inc., together with its auxiliaries, explores for and produces precious metals in the Americas. The company primarily produces silver, in addition to gold, lead, and zinc. Its principal project is the Escobal project located in Southeast Guatemala. The company was formerly known as CKM Resources Inc. and changed its name to Tahoe Resources Inc. in January 2010. Tahoe Resources Inc. was incorporated in 2009 and is headquartered in Reno, Nevada.
Finally, Arrowhead Research Corp (NASDAQ:ARWR), gained 9.68%, to $6.27.
Arrowhead Research Corporation (ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, recently declared that it has nominated ARC-HIF2 as its first therapeutic candidate delivered using a new Dynamic Polyconjugate™ (DPC™) designed to target tissues outside of the liver. Arrowhead believes that ARC-HIF2, which uses RNA interference to silence transcription factor hypoxia-inducible factor 2α (HIF-2α), is a promising new candidate for the treatment of clear cell renal cell carcinoma (ccRCC). The company will present preclinical data at the European Cancer Congress 2015 (ECC2015) in Vienna on September 27 in a session starting at 16:45 CEST. In a poster titled “HIF-2α targeting with a novel RNAi delivery platform as therapy for renal cell carcinoma,” (abstract #353), Arrowhead scientists will show data suggesting that HIF-2α inhibition through RNA interference may significantly impact late stage ccRCC progression. The company is in the process of manufacturing scale up to allow for initiation of IND-enabling studies. Timing for anticipated regulatory submission will be declared in the future.
ARC-HIF2 is designed to inhibit the production of HIF-2α, which has been linked to tumor progression and metastasis in ccRCC. ARC-HIF2 employs a novel extrahepatic-targeted DPC™ that comprises a membrane active polymer to promote RNAi trigger endosomal release, an active ligand that targets the DPC™ to tumor cells, reversible masking to prevent polymer activity proceeding to cellular uptake, and an RNAi trigger to HIF-2α conjugated directly to the DPC™.
Arrowhead Research Corporation develops novel drugs to treat intractable diseases in the United States. The company’s principal product candidates comprise ARC-520, an RNAi-based therapeutic that is in Phase IIa clinical trial to treat chronic hepatitis B virus infection; and ARC-AAT, a novel unlocked nucleobase analog containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. Its platform technology comprise Dynamic Polyconjugate platform, an RNAi delivery system that addresses multiple organ systems and cell types.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
